Linoleic Acid

Linoleic Acid

SCHEMBL3357720

CCCCC/C=C\C/C=C\CCCCCCCC(=O)O.N=C(N)NCCC[C@H](N)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Linoleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 5/20 0.56
PPARG P37231 5/20 0.56
F7 P08709 4/20 0.56
F3 P13726 4/20 0.56
PPARD Q03181 4/20 0.56
PPARA Q07869 4/20 0.56
FFAR1 O14842 3/20 0.56
PTGS1 P23219 2/20 0.56
LMNA P02545 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP19A1 P11511 2/20 0.56
FABP4 P15090 2/20 0.56
HPGD P15428 2/20 0.56
ALOX15 P16050 2/20 0.56
NR4A2 P43354 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
DUSP3 P51452 1/20 0.56
PTPN7 P35236 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Linoleic Acid SCHEMBL3357717 1.00 KDM4E (0.59) KDM4EALDH1A1PPARGF7F3
Arachidonic Acid SCHEMBL5807411 0.97 MEN1 (0.58) KDM4EALDH1A1PPARGF7F3
Arachidonic Acid SCHEMBL5807415 0.97 MEN1 (0.58) KDM4EALDH1A1PPARGF7F3
Oleic Acid SCHEMBL1736035 0.97 EPHX2 (0.57) KDM4EPPARGF7F3PPARD
Nervonic Acid SCHEMBL20694895 0.97 EPHX2 (0.57) KDM4EPPARGF7F3PPARD
Oleic Acid SCHEMBL1287108 0.97 EPHX2 (0.57) KDM4EPPARGF7F3PPARD
Arginine SCHEMBL1690131 0.90 NOD1 (0.54) ALDH1A1PPARGPPARDPPARAFFAR1
Decanoic Acid SCHEMBL11052064 0.90 NOD1 (0.54) ALDH1A1PPARGPPARDPPARAFFAR1
Decanoic Acid SCHEMBL6040143 0.90 NOD1 (0.54) ALDH1A1PPARGPPARDPPARAFFAR1
Stearic Acid SCHEMBL1287109 0.90 NOD1 (0.54) ALDH1A1PPARGPPARDPPARAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109890361-B Compositions containing linoleic acid 太阳星光齿磨公司 2023-02-24 CN disclosed
EP-2668939-B1 COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID SUNSTAR INC (JP) 2020-06-17 EP disclosed
US-10472379-B2 Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors GARNETT MCKEEN LAB, INC. 2019-11-12 US disclosed
EP-3533437-A1 COMPOSITION CONTAINING LINOLEIC ACID Sunstar Inc. (JP) 2019-09-04 EP disclosed
US-20190247290-A1 COMPOSITION CONTAINING LINOLEIC ACID SUNSTAR INC. (JP) 2019-08-15 US disclosed
US-20180051045-A1 RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS GARNETT MCKEEN LAB, INC. 2018-02-22 US disclosed
WO-2017200792-A1 RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS GARNETT MCKEEN LAB, INC. (US) 2017-11-23 WO disclosed
US-9605012-B2 Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases GARNETT MCKEEN LABORATORY, INC. (US) 2017-03-28 US disclosed
US-8940312-B2 Composition containing polyunsaturated fatty acid SUNSTAR INC. (JP) 2015-01-27 US disclosed
WO-2014164902-A9 PALLADIUM-RUTHENIUM-ZINC-ORGANO COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES GARNETT MCKEEN LABORATORY, INC. (US) 2014-12-24 WO disclosed
WO-2014164902-A1 PALLADIUM-RUTHENIUM-ZINC-ORGANO COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES GARNETT MCKEEN LABORATORY, INC. (US) 2014-10-09 WO disclosed
EP-2668939-A1 COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID SUNSTAR INC. (JP) 2013-12-04 EP disclosed
US-20130287827-A1 COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID SUNSTAR INC. (JP) 2013-10-31 US disclosed
WO-2010046542-A1 METHOD FOR PREPARING MODIFIED FIBER PRODUCTS OY KESKUSLABORATORIO - CENTRALLABORATORIUM AB (FI) 2010-04-29 WO disclosed
US-6669932-B2 Mixture of unsaturated fatty acid, phosphatides, antioxidizer, protein and mucopolysaccharides SUNSTAR INC. (JP) 2003-12-30 US disclosed
CN-1125634-C Skin-lightening cosmetic SUNSTAR INC (JP) 2003-10-29 CN disclosed
US-20030103916-A1 SKIN-WHITENING COSMETIC SUNSTAR INC. (JP) 2003-06-05 US disclosed
EP-0992236-B1 SKIN-LIGHTENING COSMETIC SUNSTAR INC (JP) 2003-04-02 EP disclosed
EP-0992236-A1 SKIN-LIGHTENING COSMETIC Sunstar Inc. (JP) 2000-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472379-B2 Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors SGMS2, SGMS1, SMPD4 KDM4E 3334/4885ALDH1A1 4354/4885PPARG 4114/4885
US-20180051045-A1 RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS SGMS2, SGMS1, SMPD4 KDM4E 3334/4885ALDH1A1 4354/4885PPARG 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.